GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heron Therapeutics Inc (NAS:HRTX) » Definitions » EPS without NRI

HRTX (Heron Therapeutics) EPS without NRI : $-0.16 (TTM As of Sep. 2024)


View and export this data going back to 1987. Start your Free Trial

What is Heron Therapeutics EPS without NRI?

Heron Therapeutics's earnings per share without non-recurring items for the three months ended in Sep. 2024 was $-0.03. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.16.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 31.60% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 17.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Heron Therapeutics's EPS without NRI or its related term are showing as below:

HRTX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -107.7   Med: 9.65   Max: 69.5
Current: 31.6

During the past 13 years, Heron Therapeutics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 69.50% per year. The lowest was -107.70% per year. And the median was 9.65% per year.

HRTX's 3-Year EPS without NRI Growth Rate is ranked better than
80.63% of 1239 companies
in the Biotechnology industry
Industry Median: 4.6 vs HRTX: 31.60

Heron Therapeutics's EPS (Diluted) for the three months ended in Sep. 2024 was $-0.03. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.16.

Heron Therapeutics's EPS (Basic) for the three months ended in Sep. 2024 was $-0.03. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.16.


Heron Therapeutics EPS without NRI Historical Data

The historical data trend for Heron Therapeutics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heron Therapeutics EPS without NRI Chart

Heron Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.50 -2.50 -2.24 -1.67 -0.80

Heron Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.17 -0.05 -0.02 -0.06 -0.03

Competitive Comparison of Heron Therapeutics's EPS without NRI

For the Biotechnology subindustry, Heron Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heron Therapeutics's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heron Therapeutics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Heron Therapeutics's PE Ratio without NRI falls into.



Heron Therapeutics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Heron Therapeutics  (NAS:HRTX) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Heron Therapeutics EPS without NRI Related Terms

Thank you for viewing the detailed overview of Heron Therapeutics's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Heron Therapeutics Business Description

Traded in Other Exchanges
Address
4242 Campus Point Court, Suite 200, San Diego, CA, USA, 92121
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Executives
William P Forbes officer: EVP, Chief Development Officer C/O SALIX PHARMACEUTICALS, LTD., 8510 COLONNADE CENTER DRIVE, RALEIGH NC 27615
Adam Morgan other: See Footnote 2 1055B POWERS PLACE, ALPHARETTA GA 30009
Ira Duarte officer: EVP, Chief Financial Officer 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Craig A Collard director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Kevin Kotler director C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Velan Capital Master Fund Lp other: See Footnote 2 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Management Llc other: See Footnote 2 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Holdings Llc other: See Footnote 2 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Investment Management Lp other: See Footnote 2 1055B POWERS PLACE, ALPHARETTA GA 30009
David Efraim Rosen other: See Footnote 1 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Rubric Capital Management Lp other: See Footnote 1 155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
Balaji Venkataraman other: See Footnote 2 FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Kimberly Manhard director C/O HERON THERAPEUTICS, INC, 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO CA 92121
Craig A Johnson director C/O PURE BIOSCIENCE, 1725 GILLESPIE WAY, EL CAJON CA 92020
Waage Christian director RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121